A. Schuller

发表

Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.

Rhys D O Jones, Shenghua Wen, M. Ashford, 2021, Molecular pharmaceutics.

Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity

James D. Clarke, M. Congreve, B. Linghu, 2020, Journal for ImmunoTherapy of Cancer.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Paul D. Smith, S. Grosskurth, R. Wilkinson, 2017, Journal of Immunotherapy for Cancer.

Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo.

C. Conover, J. Pintar, A. Schuller, 2008, Molecular endocrinology.

Generation of Antisera to Mouse Insulin-Like Growth Factor Binding Proteins (IGFBP)-1 to -6: Comparison of IGFBP Protein and Messenger Ribonucleic Acid Localization in the Mouse Embryo1.

E. Zwarthoff, N. Dits, J. Pintar, 1999, Endocrinology.

Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to -6: comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryo.

E. Zwarthoff, N. Dits, J. Pintar, 1999, Endocrinology.

Gene expression of the IGF binding proteins during post-implantation embryogenesis of the mouse; comparison with the expression of IGF-I and -II and their receptors in rodent and human.

E. Zwarthoff, I. D. de Jong, J. V. van Neck, 1993, Advances in experimental medicine and biology.

A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity

Rhys D O Jones, R. Anjum, C. D’Cruz, 2020, British journal of pharmacology.

Regulation of insulin-like growth factor (IGF)-binding protein-6 and mannose 6-phosphate/IGF-II receptor expression in IGF-IL-overexpressing NIH 3T3 cells.

T. Braulke, A. Schuller, U. Matzner, 1995, Molecular endocrinology.

Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5.

T. Ludwig, J. Pintar, J. Frystyk, 2006, Molecular endocrinology.

Hypoglycaemia associated with the production of insulin‐like growth factor II and insulin‐like growth factor binding protein 6 by a haemangiopericytoma

J. Maassen, H. Pinedo, J. van Doorn, 1999, Clinical endocrinology.

Global profiling of phosphopeptides by titania affinity enrichment.

M. Follettie, Jiang Wu, Quazi Shakey, 2007, Journal of proteome research.

Expression of growth factors and receptors during specific phases in regenerating urothelium after acute injury in vivo.

T. H. van der Kwast, T. Kwast, M. Vermey, 1994, The American journal of pathology.

IGF, type I IGF receptor and IGF-binding protein mRNA expression in the developing mouse lung.

E. Zwarthoff, J. V. van Neck, S. Drop, 1995, Journal of molecular endocrinology.

Gene expression of the six insulin-like growth factor binding proteins in the mouse conceptus during mid- and late gestation.

E. Zwarthoff, S. Drop, A. Schuller, 1993, Endocrinology.

The heterogeneous distribution of extracellular adenosine reveals a myeloid-dependent axis, shaping the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

D. Jodrell, B. P. Kaistha, F. Richards, 2022, bioRxiv.

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

E. Hennessy, S. Fawell, B. Davies, 2021, Communications biology.

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

D. Jodrell, B. P. Kaistha, F. Richards, 2022, bioRxiv.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

R. Mosher, W. Sellers, P. Finan, 2010, Proceedings of the National Academy of Sciences.

Insulin-like growth factor binding protein-2, 28 kDa and 24 kDa insulin-like growth factor binding protein levels are decreased in fluid of dominant follicles, obtained from normal and polycystic ovaries

E. Zwarthoff, B. Fauser, S. Drop, 1993, Regulatory Peptides.

Mouse insulin-like growth factor binding protein-6: expression, purification, characterization and histochemical localization

P. Breuer, T. Braulke, J. Scharf, 1998, Molecular and Cellular Endocrinology.

Small Molecule Therapeutics Preclinical Evaluation of the WEE 1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013 .

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Paul D. Smith, S. Grosskurth, R. Wilkinson, 2017, Journal for immunotherapy of cancer.

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

J. A. Hendricks, David M. Wilson, S. Kazmirski, 2018, Nature Communications.

Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice

Joshua F. Nitsche, G. Pasternak, J. Pintar, 1999, Neuron.

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

W. Sellers, Guizhi Yang, C. Kowal, 2014, mAbs.

Genetic Dissociation of Opiate Tolerance and Physical Dependence in δ-Opioid Receptor-1 and Preproenkephalin Knock-Out Mice

G. Pasternak, J. Pintar, A. Schuller, 2002, The Journal of Neuroscience.

Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice

R. Leurs, J. Pintar, H. Timmerman, 2000, Brain Research.

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

Weiguo Qing, C. Reimer, C. D’Cruz, 2016, Oncotarget.

An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.

W. Sellers, J. Gu, C. Arteaga, 2013, Cancer research.

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

W. Sellers, P. Schultz, Jennifer L. Harris, 2013, Proceedings of the National Academy of Sciences.

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Tristan J. Lubinski, E. Hennessy, M. Garnett, 2020, Clinical Cancer Research.

Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene.

T. Wood, J. Pintar, L. Rogler, 2000, Molecular endocrinology.

Expression of IGF system genes during T-antigen driven pituitary tumorigenesis.

M. Low, J. Pintar, A. Schuller, 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Cellular actions of opioids on periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR‐1

E. E. Bagley, J. Pintar, S. Hack, 2003, British journal of pharmacology.

Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family.

J. Pintar, A. Schuller, J. Cerro, 1995, Progress in growth factor research.

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

G. Daley, C. Paweletz, P. Jänne, 2021, Science Translational Medicine.

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

D. Gao, Jihye Kim, S. Eckhardt, 2016, Oncotarget.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Rhys D O Jones, S. Cairo, S. Fawell, 2015, Clinical Cancer Research.

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013, Molecular Cancer Therapeutics.

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

H. Hirsch, M. Ayers, A. Loboda, 2014, PloS one.

Retention of heroin and morphine–6β–glucuronide analgesia in a new line of mice lacking exon 1 of MOR–1

G. Pasternak, J. Pintar, Ying-Xian Pan, 1999, Nature Neuroscience.

Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene.

Bao Hoang, T. Wood, J. Pintar, 2007, Endocrinology.

Localization of the epitope of a monoclonal antibody against human insulin-like growth factor binding protein-1, functionally interfering with insulin-like growth factor binding.

E. Zwarthoff, S. Drop, A. Schuller, 1993, Growth regulation.

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Z. Cooper, A. Waage, A. Sundan, 2020, Journal for immunotherapy of cancer.

μ‐opioid receptor modulation of calcium channel current in periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR‐1

J. Pintar, M. Connor, M. Christie, 1999, British journal of pharmacology.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

P. Bunn, Jihye Kim, A. Tan, 2016, Clinical Cancer Research.

Mu‐opioid receptor knockout mice show diminished food‐anticipatory activity

R. van den Bos, M. Kas, B. Spruijt, 2004, The European journal of neuroscience.

Structural aspects of the IGFBP family.

E. Zwarthoff, S. Drop, A. Brinkman, 1992, Growth regulation.

Enzymatic Characterization of the Pancreatic Islet-specific Glucose-6-Phosphatase-related Protein (IGRP)*

L. Tartaglia, Qing Yang, T. Parsons, 2004, Journal of Biological Chemistry.

Female preproenkephalin-knockout mice display altered emotional responses.

D. Pfaff, S. Ogawa, R. Bodnar, 2001, Proceedings of the National Academy of Sciences of the United States of America.

A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model

Francoise Powell, C. Reimer, Kate F. Byth, 2014 .

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

W. Sellers, S. Fawell, D. Stover, 2012 .

The six insulin-like growth factor binding proteins : developmental expression and structural aspects

A. Schuller, 1994 .

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

A. Letai, L. Drew, A. Christie, 2019, Blood.

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

E. Hennessy, S. Fawell, B. Davies, 2021, Communications Biology.

cDNA cloning and mRNA expression of the six mouse insulin-like growth factor binding proteins

E. Zwarthoff, S. Drop, A. Schuller, 1994, Molecular and Cellular Endocrinology.

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma

D. Jodrell, B. P. Kaistha, F. Richards, 2023, Journal for ImmunoTherapy of Cancer.

Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer

K. Nishio, M. Velasco, Y. Kura, 2021, Immunology.

Genetic Dissociation of Opiate Tolerance and Physical Dependence in δ-Opioid Receptor-1 and Preproenkephalin Knock-Out Mice

G. Pasternak, J. Pintar, A. Schuller, 2002, The Journal of Neuroscience.

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013, Molecular Cancer Therapeutics.

Abstract 5155: Targeting tumor infiltrating myeloid cells in prostate cancer

M. D. De Velasco, K. Nishio, K. Sachsenmeier, 2023, Cancer Research.

Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation.

Dongshu Chen, Q. Sheng, S. Ettenberg, 2012 .